PMID- 19405089
OWN - NLM
STAT- MEDLINE
DCOM- 20090909
LR  - 20090616
IS  - 1098-2264 (Electronic)
IS  - 1045-2257 (Linking)
VI  - 48
IP  - 8
DP  - 2009 Aug
TI  - Integrated genomic and transcriptional analysis of the in vitro evolution of 
      telomerase-immortalized urothelial cells (TERT-NHUC).
PG  - 694-710
LID - 10.1002/gcc.20672 [doi]
AB  - Much progress has been made in identifying the molecular genetic alterations that 
      occur in bladder cancer. However, in many cases the genes targeted by these 
      alterations are not known. Telomerase immortalized human urothelial cells 
      (TERT-NHUC) are a useful resource for in vitro studies of genes involved in 
      urothelial transformation. When cultured under standard conditions they remain 
      genetically stable but when cultured under low-density conditions they exhibit 
      genetic instability and acquire chromosomal alterations. TERT-NHUC from three 
      donors were cultured at low plating density and examined at four time-points 
      during a culture period of 600 days. Analyses included population doubling 
      kinetics, array-based CGH (aCGH), chromosome counts, fluorescence in situ 
      hybridization (FISH), mutation analysis, Affymetrix gene expression analysis, 
      Western blotting for p16, anchorage-independent growth and tumorigenicity assays. 
      Alterations acquired during continued culture of TERT-NHUC at low density 
      (TERT-NHUC-L) included some observed in urothelial carcinoma (UC) cell lines and 
      primary UC. Examination of gene expression in TERT-NHUC with distinct acquired 
      genetic aberrations may pinpoint genes targeted by these alterations. Data from 
      an aCGH study of UC cell lines and primary tumors were examined for changes in 
      chromosomal regions that also showed alterations in TERT-NHUC-L. Loss of a region 
      on 2q including BOK was identified in UC cell lines and primary tumors. DNER and 
      FRAS1 were identified as potential candidate genes, whose expression is altered 
      independently of the acquisition of any genetic event.
FAU - Chapman, Emma J
AU  - Chapman EJ
AD  - Cancer Research UK Clinical Centre, St James's University Hospital, Leeds LS97TF, 
      UK.
FAU - Williams, Sarah V
AU  - Williams SV
FAU - Platt, Fiona M
AU  - Platt FM
FAU - Hurst, Carolyn D
AU  - Hurst CD
FAU - Chambers, Philip
AU  - Chambers P
FAU - Roberts, Paul
AU  - Roberts P
FAU - Knowles, Margaret A
AU  - Knowles MA
LA  - eng
GR  - C6228/A5433/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Genes Chromosomes Cancer
JT  - Genes, chromosomes & cancer
JID - 9007329
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Cell Count
MH  - Cell Culture Techniques
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Chromosome Aberrations
MH  - *Comparative Genomic Hybridization
MH  - Cyclin-Dependent Kinase Inhibitor p16/genetics/metabolism
MH  - Gene Dosage
MH  - *Gene Expression
MH  - Gene Expression Profiling/*methods
MH  - Humans
MH  - Loss of Heterozygosity
MH  - Phenotype
MH  - Ploidies
MH  - Proto-Oncogene Proteins/genetics/metabolism
MH  - Telomerase/*genetics/metabolism
MH  - Urinary Bladder Neoplasms/*genetics/metabolism
MH  - Urothelium/*cytology/*metabolism
EDAT- 2009/05/01 09:00
MHDA- 2009/09/10 06:00
CRDT- 2009/05/01 09:00
PHST- 2009/05/01 09:00 [entrez]
PHST- 2009/05/01 09:00 [pubmed]
PHST- 2009/09/10 06:00 [medline]
AID - 10.1002/gcc.20672 [doi]
PST - ppublish
SO  - Genes Chromosomes Cancer. 2009 Aug;48(8):694-710. doi: 10.1002/gcc.20672.